+287.3%
NOW vs MRNA
+561.6%
-274.3%
-64.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.0% | -2.2% | -0.7% | -2.8% |
| 7D | -2.4% | +5.5% | -7.9% | -2.9% |
| 30D | +20.5% | +158.7% | -138.2% | +3.5% |
| 3M | +18.3% | +182.1% | -163.8% | +0.1% |
| 6M | +24.1% | +151.8% | -127.8% | +5.9% |
| YTD | -7.8% | +393.6% | -401.3% | -28.3% |
| 1Y | -21.4% | +499.5% | -520.9% | -40.8% |
| 3Y | +19.5% | +29.3% | -9.8% | +3.9% |
| 5Y | +4.1% | -65.1% | +69.1% | -0.8% |
| All | +287.3% | +561.6% | -274.3% | +158.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling